Condition: Aortic Regurgitation Disease · Sponsor: IRCCS Policlinico S. Donato
To observe the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with evere native aortic regurgitation (AR) who are indicated for TAVR Data collection
This description comes directly from the study's public registry record.
Federica Rossi, Study Coordinator · 0252774984 · federica.rossi@grupposandonato.it
Mattia Ricotti, CET specialist · 0252774236 · mattia.ricotti@grupposandonato.it
Always discuss trial participation with your own doctor first.
| IRCCS Policlinico San Donato | San Donato Milanese, Milano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07075861